Artimplant Interim Report January - September 2009
VÄSTRA FRÖLUNDA, Sweden--(Business Wire)-- Regulatory News: Artimplant (STO:ARTIB): * Net revenue for the third quarter increased to SEK 5.5 million (2.3) and for January-September to SEK 18.2 million (7.5)* * The net loss for the third quarter totaled SEK 4.7 million (4.3) and for January-September SEK 13.2 million (16.6) * Earnings per share for the third quarter amounted to SEK -0.08 (-0.07) and for January-September SEK -0.22 (-0.28) * Sales of Artelon Spacer for the third quarter increased to SEK 2.5 million (1.2) and for January-September to SEK 10.7 million (4.9) * Sales of Artelon Tissue Reinforcement for the third quarter increased to SEK 2.5 million (1.1) and for January-September to SEK 6.9 million (2.5) * Emerging Medical Group was appointed as the new sales management team for Artimplant USA N.B. This is a translation from Swedish. The Swedish version shall always take precedence. Artimplant will hold a telephone conference by reason of this report on November 6, 2009 at 11 am (Swedish time). For further information see www.artimplant.com. * Figures in brackets refer to the corresponding period last year Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings. This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 6, 2009 at 08:45 AM (Swedish time). This information was brought to you by Cision http://www.cisionwire.com Artimplant Hans Rosén, CEO Phone +46 (0)31-746 56 00 / +46 (0)708 58 34 70 hans.rosen@artimplant.com or Lars-Johan Cederbrant, CFO Phone +46 (0)31-746 56 54 / +46 (0)703 01 68 54, lars-johan.cederbrant@artimplant.com Copyright Business Wire 2009
